Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Rapamune (sirolimus) for fibrofolliculomas in Birt-Hogg-Dubé syndrome
2009-012740-17Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of sirolimus in Fibrofolliculoma and Birt-Hogg-Dubé syndrome (BHDS), sponsored by Maastricht University Medical Center+. Primary endpoint: Regression of facial fibrofolliculomas. Started May 2009; status: completed.
02
Drugs
sirolimus
03
Conditions
FibrofolliculomaBirt-Hogg-Dubé syndrome (BHDS)
Beyond the preview
Go deeper on 2009-012740-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012740-17.